An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma

Journal of Controlled Release

Volumn 155, Issue 2, 2011, Pages 184-192

  Singh, Ankur ^a,c   Qin, Hong ^b   Fernandez, Irina ^a   Wei, Jinsong ^b   Lin, Jian ^a,d   Kwak, Larry W ^b   Roy, Krishnendu ^a  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d XBiotech Inc   (United States)

Author keywords

Hydrogel; Immunotherapy; Lymphoma; Microparticles; siRNA; T helper

Indexed keywords

IMMUNOTHERAPY; LYMPHOMA; MICRO-PARTICLES; SIRNA; T-HELPER;

ANTIBODIES; ANTIGENS; CELLS; CHEMOTHERAPY; DISEASES; DNA; HYDROGELS; ONCOLOGY; TUMORS; VACCINES; DISEASE CONTROL;

CYTOLOGY;

BIOMATERIAL; INTERLEUKIN 10; SMALL INTERFERING RNA; CANCER VACCINE; DNA VACCINE; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; SYNTHETIC IMMUNE PRIMING CENTER; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; B CELL LYMPHOMA; CELL EXPANSION; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; CROSS LINKING; CYTOKINE RELEASE; DENDRITIC CELL; GENE SILENCING; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNTHETIC IMMUNE PRIMING CENTER; TH1 CELL; TH17 CELL; TH2 CELL; VACCINATION; ANIMAL CELL; ANIMAL TISSUE; CANCER IMMUNIZATION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE DELIVERY SYSTEM; GENE TARGETING; IN VIVO STUDY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CROSS-LINKING REAGENTS; DELAYED-ACTION PREPARATIONS; DENDRITIC CELLS; DNA; DRUG CARRIERS; FEMALE; HYDROGELS; IMMUNOGLOBULIN IDIOTYPES; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-10; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 80054095576     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.06.008     Document Type: Conference Paper

References (31)

1. J.A. Hubbell, S.N. Thomas, and M.A. Swartz Materials engineering for immunomodulation Nature 462 2009 449 460
2. O.A. Ali, N. Huebsch, L. Cao, G. Dranoff, and D.J. Mooney Infection-mimicking materials to program dendritic cells in situ Nat. Mater. 8 2009 151 158
3. S. Baskar, C.B. Kobrin, and L.W. Kwak Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes J. Clin. Invest. 113 2004 1498 1510 (Pubitemid 39071706)
4. H. Qin, S.C. Cha, S.S. Neelapu, Y. Lou, J. Wei, Y.J. Liu, and L.W. Kwak Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity Blood 114 2009 4142 4149
5. P.A. Ruffini, S.S. Neelapu, L.W. Kwak, and A. Biragyn Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines Haematologica 87 2002 989 1001
6. P.A. Ruffini, A. Biragyn, and L.W. Kwak Recent advances in multiple myeloma immunotherapy Biomed. Pharmacother. 56 2002 129 132 (Pubitemid 34442473)
7. A. Biragyn, M. Surenhu, D. Yang, P.A. Ruffini, B.A. Haines, E. Klyushnenkova, J.J. Oppenheim, and L.W. Kwak Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens J. Immunol. 167 2001 6644 6653 (Pubitemid 33081603)
8. U.K. Liyanage, T.T. Moore, H.G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J.A. Drebin, S.M. Strasberg, T.J. Eberlein, P.S. Goedegebuure, and D.C. Linehan Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma J. Immunol. 169 2002 2756 2761 (Pubitemid 34921025)
9. H. Tanaka, J. Tanaka, J. Kjaergaard, and S. Shu Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes J. Immunother. 25 2002 207 217 (Pubitemid 34533310)
10. Z. Liu, J.H. Kim, L.D. Falo Jr., and Z. You Tumor regulatory T cells potently abrogate antitumor immunity J. Immunol. 182 2009 6160 6167
11. L. Xu, W. Xu, Z. Jiang, F. Zhang, Y. Chu, and S. Xiong Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy Cancer Biol. Ther. 8 2009 66 72
12. G. Liu, H. Ng, Y. Akasaki, X. Yuan, M. Ehtesham, D. Yin, K.L. Black, and J.S. Yu Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response Eur. J. Immunol. 34 2004 1680 1687 (Pubitemid 39256050)
13. A. Singh, H. Nie, B. Ghosn, H. Qin, L.W. Kwak, and K. Roy Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells Mol. Ther. 16 2008 2011 2021
14. O.A. Ali, D. Emerich, G. Dranoff, and D.J. Mooney In situ regulation of DC subsets and T cells mediates tumor regression in mice Sci. Transl. Med. 1 2009 8ra19
15. F. Salazar-Onfray, M. Petersson, L. Franksson, M. Matsuda, T. Blankenstein, K. Karre, and R. Kiessling IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression J. Immunol. 154 1995 6291 6298
16. G. Gerlini, A. Tun-Kyi, C. Dudli, G. Burg, N. Pimpinelli, and F.O. Nestle Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions Am. J. Pathol. 165 2004 1853 1863 (Pubitemid 39578365)
17. A. Singh, S. Suri, and K. Roy In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells Biomaterials 30 2009 5187 5200
18. T. Tarasenko, H.K. Kole, A.W. Chi, M.M. Mentink-Kane, T.A. Wynn, and S. Bolland T cell-specific deletion of the inositol phosphatase SHIP reveals its role in regulating Th1/Th2 and cytotoxic responses Proc. Natl. Acad. Sci. U.S.A. 104 2007 11382 11387 (Pubitemid 47175149)
19. A. Biragyn, K. Tani, M.C. Grimm, S. Weeks, and L.W. Kwak Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity Nat. Biotechnol. 17 1999 253 258 (Pubitemid 29122633)
20. S. Pai Kasturi, H. Qin, K.S. Thomson, S. El-Bereir, S.C. Cha, S. Neelapu, L.W. Kwak, and K. Roy Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles J. Control. Release 113 2006 261 270 (Pubitemid 43977789)
21. B.A. Imhof, and M. Aurrand-Lions Adhesion mechanisms regulating the migration of monocytes Nat. Rev. Immunol. 4 2004 432 444 (Pubitemid 38745555)
22. J.L. Langowski, R.A. Kastelein, and M. Oft Swords into plowshares: IL-23 repurposes tumor immune surveillance Trends Immunol. 28 2007 207 212 (Pubitemid 46654872)
23. P. Muranski, A. Boni, P.A. Antony, L. Cassard, K.R. Irvine, A. Kaiser, C.M. Paulos, D.C. Palmer, C.E. Touloukian, K. Ptak, L. Gattinoni, C. Wrzesinski, C.S. Hinrichs, K.W. Kerstann, L. Feigenbaum, C.C. Chan, and N.P. Restifo Tumor-specific Th17-polarized cells eradicate large established melanoma Blood 112 2008 362 373
24. M. Numasaki, J. Fukushi, M. Ono, S.K. Narula, P.J. Zavodny, T. Kudo, P.D. Robbins, H. Tahara, and M.T. Lotze Interleukin-17 promotes angiogenesis and tumor growth Blood 101 2003 2620 2627 (Pubitemid 36857622)
25. B.Z. Packard, W.G. Telford, A. Komoriya, and P.A. Henkart Granzyme B activity in target cells detects attack by cytotoxic lymphocytes J. Immunol. 179 2007 3812 3820
26. A.M. Chinnaiyan, W.L. Hanna, K. Orth, H. Duan, G.G. Poirier, C.J. Froelich, and V.M. Dixit Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3 Curr. Biol. 6 1996 897 899 (Pubitemid 26324634)
27. R.M. Spaapen, H.M. Lokhorst, K. van den Oudenalder, B.E. Otterud, H. Dolstra, M.F. Leppert, M.C. Minnema, A.C. Bloem, and T. Mutis Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis J. Exp. Med. 205 2008 2863 2872
28. B. Bierie, and H.L. Moses Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer Nat. Rev. Cancer 6 2006 506 520 (Pubitemid 43980540)
29. R. Derynck, R.J. Akhurst, and A. Balmain TGF-beta signaling in tumor suppression and cancer progression Nat. Genet. 29 2001 117 129 (Pubitemid 32952643)
30. L. Gorelik, and R.A. Flavell Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells Nat. Med. 7 2001 1118 1122 (Pubitemid 33010019)
31. Q. Zhang, X.J. Yang, S.D. Kundu, M. Pins, B. Javonovic, R. Meyer, S.J. Kim, N.M. Greenberg, T. Kuzel, R. Meagher, Y. Guo, and C. Lee Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle Mol. Cancer Ther. 5 2006 1733 1743 (Pubitemid 44323241)